Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Cancer

• Publication date

  1995-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(19950701)76:1<96::AID-CNCR2820760114>3.0.CO;2-EPMID 8630883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

  1993cited by this paper
• Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.

  1993cited by this paper
• Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

  1992cited by this paper
• The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.

  1992cited by this paper
• Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer.

  1990cited by this paper
• A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

  1990cited by this paper
• Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

  1990cited by this paper
• Suppression of Plasma Androgen Levels with a Combination Therapy of Depot-Estrogen (TuristeronR) and DexamethasoneR in Patients with Prostatic Cancer

  1989cited by this paper
• Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

  1989cited by this paper
• The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.

  1988cited by this paper
• Carcinoma of the prostate. Hormonal therapy

  1987cited by this paper
• Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer.

  1987cited by this paper
• Adrenal androgen blockade in relapsed prostate cancer.

  1985cited by this paper
• Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro.

  1974cited by this paper
• Cortisone treatment in advanced carcinoma of the prostate.

  1954cited by this paper
• Cortisone treatment in advanced carcinoma of the prostate.

  1953cited by this paper
• Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen.

  1945cited by this paper

• Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

  2026cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

  2025cites this paper
• Is the glucocorticoid receptor a key player in prostate cancer?: A literature review

  2022cites this paper
• 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

  2022cites this paper
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

  2022cites this paper
• The Challenges and Emerging Opportunities of Targeting Cytokines and Chemokine-Driven Inflammatory Signals in Metastatic Castrate-Resistant Prostate Cancer.

  2022cites this paper
• Androgen receptor signalling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration sensitive prostate cancer.

  2021cites this paper
• An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer

  2021cites this paper
• Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer.

  2021cites this paper
• Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

  2021cites this paper
• 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

  2021cites this paper
• Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!

  2021cites this paper
• Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cites this paper
• 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

  2019cites this paper
• Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis

  2019cites this paper
• Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles

  2018cites this paper
• Androgen receptor reverts dexamethasone-induced inhibition of prostate cancer cell proliferation and migration

  2018cites this paper
• Corticosteroid Therapy for CRPC

  2018cites this paper
• Clinical Results of Secondary Hormonal Treatment

  2018cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• Targeting the glucocorticoid receptor for a combinatory treatment strategy for castration resistant prostate cancer

  2018cites this paper
• Molecular underpinnings of enzalutamide resistance.

  2018cites this paper
• Comparing the rules of engagement of androgen and glucocorticoid receptors

  2017cites this paper
• Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer

  2017cites this paper
• Kortikoide im Management des fortgeschrittenen Prostatakarzinoms

  2017cites this paper
• The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside

  2017cites this paper
• Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy

  2016cites this paper
• Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer

  2016cites this paper
• Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer.

  2016cites this paper
• Second-Line Hormonal for Castrate-Resistant Prostate Cancer

  2016cites this paper
• A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.

  2016cites this paper
• Reconsideration of Hormonal Therapy in the Era of Next‐ Generation Hormonal Therapy

  2016cites this paper
• Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer

  2016cites this paper
• A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.

  2015cites this paper
• Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

  2015cites this paper
• The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors

  2015cites this paper
• Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.

  2015cites this paper
• [Management of non metastatic castration resistant prostate cancer].

  2015cites this paper
• Recepteur d'origine nantais (RON), more than a kinase: Role in castrate‐resistant prostate cancer

  2015cites this paper
• The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

  2015cites this paper
• Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling.

  2015cites this paper
• Corticosteroids in the Management of Prostate Cancer: A Critical Review

  2015cites this paper
• Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

  2014influential citation
• Driver or Passenger - Roles of the Glucocorticoid Receptor in Castration Resistance Prostate Cancers

  2014cites this paper
• Emerging mechanisms of enzalutamide resistance in prostate cancer

  2014cites this paper
• Management of Castration Resistant Prostate Cancer

  2014cites this paper
• Dihydrotestosterone enhances castration‐resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway

  2014cites this paper
• Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.

  2014cites this paper
• Verläufe ambulanter Docetaxel-Firstline-Chemotherapien bei Patienten mit kastrationsresistentem Prostatakarzinom

  2014cites this paper
• Glucocorticoids and prostate cancer treatment: friend or foe?

  2014cites this paper
• An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study

  2014cites this paper
• Redirecting and Modulating Rationalizations of Tumor-Immanent Normative Functions in Castration-Resistant Prostate Cancer

  2013cites this paper
• CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.

  2013cites this paper
• Management of castration-resistant prostate cancer: a global approach.

  2012cites this paper
• Effects of acute treatment with dexamethasone on hemodynamic and histopathological changes in rats

  2012cites this paper
• The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

  2012cites this paper
• Steroid Receptors in Renal Cell Carcinoma

  2012cites this paper
• Treatment of Castration-Resistant Prostate Cancer

  2012cites this paper
• Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?

  2012cites this paper
• Current management of prostate cancer: dilemmas and trials.

  2012cites this paper
• chapter 110 - Treatment of Castration-Resistant Prostate Cancer

  2012cites this paper
• 5 Steroid Receptors in Renal Cell Carcinoma

  2012cites this paper
• Treatment Options in Hormone-Refractory Prostate Cancer

  2012cites this paper
• Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study.

  2011cites this paper
• Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.

  2011cites this paper
• Current Options and Future Directions in Castrate Resistant Prostate (CRPC)

  2011cites this paper
• Steroid receptor expression in thymomas and thymic carcinomas

  2011cites this paper
• Docetaxel as a vital option for corticosteroid-refractory prostate cancer

  2011cites this paper
• Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.

  2011cites this paper
• Glucocorticoid receptor signaling and prostate cancer.

  2011cites this paper
• Materiales y métodos

  2010cites this paper
• Modular therapy approach in metastatic castration-refractory prostate cancer

  2010cites this paper
• Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

  2010cites this paper
• Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.

  2010cites this paper
• Current management of castrate-resistant prostate cancer.

  2010cites this paper
• Guidelines for the management of castrate-resistant prostate cancer.

  2010cites this paper
• Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer

  2010influential citation
• Thalidomide and Analogs

  2010cites this paper
• Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients.

  2009cites this paper
• Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer

  2009cites this paper
• Systems Biology: A Therapeutic Target for Tumor Therapy

  2008cites this paper
• Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients

  2008cites this paper
• Therapeutic Approach to Castration-resistant Prostate Cancer

  2008cites this paper
• Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer

  2007cites this paper
• Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells.

  2007cites this paper
• [Metastatic prostate cancer treatment in the elderly].

  2007cites this paper
• Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells

  2007cites this paper
• Hormone-refractory prostate cancer: choosing the appropriate treatment option.

  2007cites this paper
• Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer

  2007cites this paper
• Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy.

  2007cites this paper
• Glucocorticoids Suppress TumorAngiogenesis and In vivo Growth of Prostate Cancer Cells

  2006influential citation
• Glucocorticoids SuppressTumor Lymphangiogenesis of Prostate Cancer Cells

  2006cites this paper
• Glucocorticoids Suppress Tumor Lymphangiogenesis of Prostate Cancer Cells

  2006cites this paper
• Treatment with prednisolone of hormone-refractory prostate cancer.

  2006cites this paper
• Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth of Prostate Cancer Cells

  2006influential citation
• Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer.

  2006cites this paper
• Phase II trial of high‐dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen‐independent prostate cancer

  2006cites this paper
• Immunotherapy for prostate cancer

  2006cites this paper
• The case for secondary hormonal therapies in the chemotherapy age.

  2006cites this paper